Capricor跳涨,因研究显示deramiocel的长期疗效(CAPR:NASDAQ)
· seekingalpha.com
Capricor (CAPR) 因新的 deramiocel HOPE-3 24个月杜氏肌营养不良症数据而飙升,该数据在11月FDA决定前公布。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...